Akademibokhandeln
James Murrough, Dennis Charney - Therapies for Treatment-Resistant Depression, Häftad

Häftad, Engelska, 2025

Therapies for Treatment-Resistant Depression

Neuropharmacology and Neurostimulation

Av James Murrough, Dennis Charney

2649 kr

Beställningsvara. Skickas inom 11-20 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

Beskrivning

Therapies for Treatment-Resistant Depression: Neuropharmacology and Neurostimulation provides readers with an authoritative, comprehensive and targeted treatment guide. The first section reviews the essential knowledge and methods of clinical neuroscience and neuropsychopharmacological techniques as they apply to novel treatment discovery for depression. This is followed by detailed chapters on ketamine, esketamine, other glutamate modulators in development, GABA modulators, neuropeptides, anti-inflammatory agents, and other classes of novel therapeutics under study for TRD and related mood disorders.

The last section consists of a set of chapters of special interest that includes current and future research directions, development of psilocybin-based interventions and other psychedelic compounds currently under study for TRD and advances in biomarker-guided and personalized treatment. Edited by world renowned experts in the field, this book is the ultimate resource for researchers and clinicians.



  • Defines treatment-resistant depression, including epidemiology
  • Outlines neuroimaging and brain-based biomarkers in treatment-resistant depression using patient data
  • Reviews safety and monitoring protocols of ketamine in clinical care
Produktinformation
  • Utgivningsdatum: 2025-08-05
  • Mått: 191 x 235 x 24 mm
  • Vikt: 1 000 g
  • Format: Häftad
  • Språk: Engelska
  • Antal sidor: 410
  • Förlag: Elsevier Science
  • ISBN: 9780443160059
Utforska kategorier
Mer information

I am Professor of Psychiatry and Neuroscience, Vice Chair for Clinical Research in Psychiatry, and Director of the Depression and Anxiety Center for Discovery and Treatment (DAC) at the Icahn School of Medicine at Mount Sinai (ISMMS). My program of research utilizes molecular, neuroimaging, and experimental therapeutics approaches aimed at elucidating the fundamental mechanisms underlying stress-related disorders in humans, including major depressive disorder (MDD), posttraumatic stress disorder (PTSD) and anxiety disorders. The overall goal of my research is to advance the treatment of stress-related disorders through an enhanced understanding of disease pathogenesis and therapeutic mechanisms of action. Dennis S. Charney is an American biological psychiatrist and researcher, with expertise in the neurobiology and treatment of mood and anxiety disorders. He is the author of Neurobiology of Mental Illness, The Physician's Guide to Depression and Bipolar Disorders and Molecular Biology for the Clinician, as well as the author of over 600 original papers and chapters. In 2022, he was listed #52 on Research.com's "Top Medicine Scientists in the United States," with an h-index of 194 with 146,109 citations across 651 publications. Charney is known for demonstrating that ketamine is effective for treating depression. Ketamine's use as a rapidly-acting anti-depressant is recognized as a breakthrough treatment in mental illness.

Butikslager

Ej i lager i butik.

Betyg & recensioner

0 recensioner

Inga recensioner tillgängliga.